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Abstract: Early administration of antibiotics is associated with better survival in sepsis, thus screening
and early detection for sepsis is of clinical importance. Current risk stratification scores used for
bedside detection of sepsis, for example Quick Sequential Organ Failure Assessment (qSOFA) and
National Early Warning Score 2 (NEWS2), are primarily validated for death and intensive care.
The primary aim of this study was to compare the diagnostic accuracy of qSOFA and NEWS2 for
a composite outcome of sepsis with organ dysfunction, infection-related mortality within <72 h,
or intensive care due to an infection. Retrospective analysis of data from two prospective, observational,
multicentre, convenience trials of sepsis biomarkers at emergency departments were performed.
Cohort A consisted of 526 patients with a diagnosed infection, 288 with the composite outcome.
Cohort B consisted of 645 patients, of whom 269 had a diagnosed infection and 191 experienced
the composite outcome. In Cohort A and B, NEWS2 had significantly higher area under receiver
operating characteristic curve (AUC), 0.80 (95% CI 0.75–0.83) and 0.70 (95% CI 0.65–0.74), than qSOFA,
AUC 0.70 (95% CI 0.66–0.75) and 0.62 (95% CI 0.57–0.67) p < 0.01 and, p = 0.02, respectively for the
composite outcome. NEWS2 was superior to qSOFA for screening for sepsis with organ dysfunction,
infection-related mortality or intensive care due to an infection both among infected patients and
among undifferentiated patients at emergency departments.
Keywords: qSOFA; early warning score; NEWS2; sepsis; validation studies
1. Introduction
The incidence of sepsis is high (600/100 000 persons per year), with an in-hospital mortality of
16% [1,2]. Early administration of antibiotics is associated with better survival, thus screening and
early detection for sepsis is of clinical importance [3]. Numerous scores have been devised both for
detection and prognostication of sepsis. These include Systemic Inflammatory Response Syndrome
(SIRS), Quick Sequential Organ Failure Assessment (qSOFA) and most recently, National Early Warning
Score 2 (NEWS2) (Table S1) [4–7]. The use of these scores has also led to sepsis alert systems in which
patients considered to be at high risk of critical illness are prioritized and treated according to sepsis
bundles [8,9].
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qSOFA was both derived and primarily validated using death and prolonged intensive care as
outcomes [4,10]. However, qSOFA’s accuracy when used to predict sepsis is lower [11,12].
Although qSOFA was developed to identify those with risk of sepsis among infected patients,
the authors recommended that positive qSOFA criteria should also prompt consideration of possible
infection in patients not previously recognized as infected [13]. NEWS2 is a modified version of NEWS,
which is commonly used in British hospitals for identifying patients at risk for deterioration [7].
For use as a screening tool amongst undifferentiated patients in the Emergency Department
(ED), a score should be capable of discriminating sepsis from other competing diagnoses, as well
as predicting the development of sepsis among infected patients [14]. Therefore, in this study we
evaluated qSOFA and NEWS2 for their ability to detect sepsis, both among infected patients as well as
in a broader cohort consisting of both infected and non-infected patients.
Although elevated serum lactate levels were originally considered for inclusion in qSOFA, lactate
levels had little effect upon how patients were classified [13]. Heparin binding protein (HBP) is a
granule protein, released by neutrophils in response to bacterial products [15–17]. HBP increases
vascular leakage, correlates with progression to septic shock and has proven to be an early biomarker
of severe sepsis in the ED [17–20].
The first aim of this study was to compare the diagnostic accuracy of qSOFA and NEWS2 for a
composite outcome of sepsis with organ dysfunction (infection and an organ dysfunction defining
severe sepsis according to sepsis-2), intensive care admission due to an infection and infection-related
mortality within 72 h from enrolment. We went on to compare the predictive performance of qSOFA
and NEWS2 for 30-day mortality, and last investigated whether including the biomarkers lactate and
HBP improved performance for qSOFA and NEWS2
2. Methods
2.1. Patients
2.1.1. Cohort A
Data were collected prospectively between 2011–2012 at EDs in an international, multicentre,
convenience sampling, observational trial of sepsis biomarkers described elsewhere [21]. Adult
patients were included at presentation if they had a suspected infection and at least one of SIRS criteria,
or self-reported fever or chills. Only patients at the Swedish sites were included in this analysis.
For details on including sites see Table S2. At enrolment, data on demography, comorbid conditions,
medication and vital signs were recorded and blood drawn for plasma. Organ dysfunction, treatment,
admission to intensive care, a diagnosis of infection and 30-days mortality was obtained from the
hospital chart and the Swedish National death registry. Patients regarded as infected, as described
below, were included. Patients discharged from the hospital, who did not die or require re-admission
within 72 h were defined as not developing any new organ-dysfunction after discharge. The study was
approved by the regional ethical board (2010/205).
2.1.2. Cohort B
Data were collected prospectively between 2015–2016 at EDs in an international multicentre,
observational trial of sepsis biomarkers [20]. For details on including sites see Table S2. At all sites
except one (Helsingborg, Sweden) inclusion took place during fixed hours each weekday. During the
time of inclusion (i.e., when study personal were present at the ED) there was no selection of patients.
The inclusion at these sites (Lund, Vancouver and Bern) resembles a study with consecutive inclusion.
Patients with one of the following parameters were included: respiratory rate >25 breaths per minute,
heart rate >120 beats per minute, altered mental awareness, systolic blood pressure (SBP) below
100 mmHg, oxygen saturation (SaO2) <90%, or <93% if ongoing treatment with oxygen. At enrolment,
data on demography, comorbid conditions, medication and vital signs were recorded and blood drawn
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for plasma. Organ dysfunction, treatment, admission to intensive care, a diagnosis of infection and
30-days mortality was obtained from the hospital chart and the Swedish National death registry.
Both infected and non-infected patients were included in the analyses. Patients discharged from the
hospital and not re-admitted within 72 h were defined as not having new organ-dysfunction after
discharge. The study was approved by the regional ethical boards (Sweden 2014/41, Bern KEK 315/14,
Vancouver H11-00505).
2.2. Definitions
We used the earlier sepsis-2 definition for organ dysfunction since this included the consensus
criteria used at the time the data were gathered and SOFA-scores were not available for patients in
Cohort A [22]. Infection-induced organ dysfunction was defined as a probable or verified infection
based on clinical presentation, laboratory results, microbiological samples and radiologic examinations,
and an acute organ dysfunction of no other apparent or pre-existing cause. For the definitions of organ
dysfunction see Table 1.
Table 1. Organ dysfunction definition.
System Values
Cardiovascular
SBP < 90 mmHg
∆SBP > −40
MAP < 70
Vasopressor
Respiratory, Cohort A SaO2 < 90%
Respiratory, Cohort B
SaO2 < 90%
For COPD SaO2 < 87%
For SaO2 90%–94% and O2 PaO2/FiO2 ratio < 300
with COPD and SaO2 87%–95% PaO2/FiO2 ratio < 250
Renal
creatinine increase > 44 µmol/L
urinary output < 0.5mL/kg/h for >2 h
initiation of dialysis
Hepatic bilirubin > 35 µmol/L
Haematologic platelet count < 100 × 109/L
INR > 1.5 unless use of anticoagulants
Metabolic lactate > 3.2 mmol/L
Systolic blood pressure (SBP), mean arterial blood pressure (MAP), oxygen saturation (SaO2), chronic obstructive
pulmonary disease (COPD), international normalized ratio (INR).
The Severinghaus equation was used to calculate Partial pressure of Oxygen/Fraction of Inspired
Oxygen (PaO2/FiO2) ratio for patients with oxygen saturation (SaO2) 90%–94% and for patients with
chronic obstructive pulmonary disorder (COPD) and SaO2 87%–95% and simultaneous oxygen supply
in Cohort B [23].
Acute neurological dysfunction was not included as an organ dysfunction defining severe sepsis,
since it was part of scores being evaluated. When evaluating the effect of adding lactate to risk
stratification scores, hyperlactaemia was excluded from the definition for severe sepsis.
The different scores were primarily evaluated against a composite outcome (hereafter called
severe infection) of severe sepsis (according to sepsis-2), admission to intensive care within 72 h due to
an infection or infection-related mortality within 72 h.
qSOFA was defined as one point for each of respiratory rate ≥ 22, SBP ≤ 100 mm Hg and altered
mental status. When calculating sensitivity and specificity, a cut-off of two points was used.
The NEWS2 definition is presented in Table S1. For the calculations of sensitivity and specificity,
the score was dichotomized at a cut-off of five points [7].
When testing for the addition of lactate to qSOFA, qSOFA was revised to a four-point score with
one point added for lactate > 2.0 mmol/L. A lactate level of >2.0 mmol/L was chosen as in the original
assessment of qSOFA [13].
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When testing for the addition of HBP to qSOFA, qSOFA was also revised to a four-point score
with one point added for HBP > 30 ng/mL.
Lactate was analysed at the clinical chemistry departments at each hospital. The reference
interval at the hospitals were lactate < 2.2 mmol/L. Hence the cut-off for organ dysfunction due to
hyperlactaemia was set at >3.2, (>1mmol/L over the normal reference value) [24].
HBP was analysed with enzyme-linked immunosorbent assay (ELISA) at a centralized laboratory.
Definitions for comorbidities are found in Table S3.
2.3. Statistical Methods
Area under receiver operating characteristic curve (AUC), sensitivity, specificity and their 95%
confidence interval (CI) were calculated. p-values for medians were calculated using a Mann–Whitney
U test, p-values for proportions were calculated using chi2 and Fishers’ exact test as appropriate and the
formula of DeLong was used for comparison of AUC. p-values below 0.05 were regarded as significant.
Patients with missing values in parameters in qSOFA and NEWS2 were excluded in the
primary analysis.
Multiple imputation of missing values that are part of the risk stratification scores or missing
values for biomarkers were executed using predictive mean matching and logistic regression with
20 imputation sets and the performances of different risk stratification scores were calculated in a
sensitivity analysis. AUCs and 95% CIs were calculated as medians of the pooled data in the imputed
data sets.
To assess the performance of NEWS2 and qSOFA in relation to the proportion of patients with
organ dysfunction a sensitivity analysis was performed. Patients were divided into the presence or
absence of organ dysfunction. Samples from respective groups were drawn (with replacement) to
mimic cohorts with the proportion of patients with organ dysfunction ranging from 1% to 99% in
steps of 1%. For each proportion of patients with organ dysfunction 100 stochastic cohorts (each with
1000 patients) were drawn and the AUC-values for qSOFA and NEWS2 were calculated and the median
was calculated and plotted.
Analyses were performed using SPSS software system version 23.0 (IBM, Armonk, NY, USA) and
R: A language and environment for statistical computing. (R Foundation for Statistical Computing,
Vienna, Austria. URL https://www.R-project.org/) with the following packages: readxl, ggplot2, grid,
gridExtra, clinfun, pROC and epiR.
3. Results
3.1. Cohort A—Patients with Suspected Infection
3.1.1. Patient Demographics
Six-hundred and forty-nine patients were eligible for the study, 94 patients without a probable
or verified infection and 29 patients with missing data were excluded. A total of 526 patients with
infection were included in the primary analysis of Cohort A. The composite outcome (consisting
of sepsis with organ dysfunction, admission to intensive care within 72 h due to an infection or
infection-related mortality within 72 h from enrolment) were found in 238 (45%) patients (Figure 1).
The 30-day mortality was 3%. Patient characteristics are presented in Table 2.
Forty-one patients included in the study, but with missing lactate or HBP-analysis were excluded
when the effect of adding lactate or HBP to qSOFA and NEWS2 were studied.
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Figure 1. Flow chart. Cohort A, patients with suspected infection and one of systemic inflammatory
response syndrome (SIRS) criteria, or self-reported fever or chills. Cohort B, patients with one
of the following parameters: respiratory rate > 25, heart rate > 120, altered mental awareness,
SBP < 100 mmHg, SaO2 < 90%, or <93% if ongoing treatment with oxygen. qSOFA (Quick Sequential
Organ Failure Assessment). NEWS2 (National Early Warning Score 2). HBP (heparin binding protein).
Table 2. Patient characteristics. Percentages within brackets.
Cohort A, n = 526 Cohort B, n = 645
With Composite
Outcome n = 238
Without
Composite
Outcome n = 288
p With CompositeOutcome n = 191
Without
Composite
Outcome n = 454
p
Age, median 70 52 <0.01 76 71 <0.01
Female, n (%) 109 (46) 125 (43) 0.60 94 (49) 218 (48) 0.80
Comorbidities n (%)
Diabetes 48 (20) 30 (10) <0.01 43 (23) 80 (18) 0.16
Cardiovascular disease 80 (34) 34 (12) <0.01 99 (52) 205 (45) 0.14
Renal disease 16 (6) 32 (13) <0.01 56 (29) 111 (24) 0.20
Liver disease 1 (0) 3 (1) 0.63 12 (6) 13 (3) 0.05
Malignancy 24 (10) 21 (7) 0.28 31 (16) 57 (13) 0.21
Immunodeficiency 9 (4) 10 (4) 1 8 (4) 6 (1) 0.04
Respiratory disease 32 (13) 22 (8) 0.03 32 (17) 50 (11) 0.05
No comorbidities 98 (41) 195 (68) <0.01 31 (16) 148 (33) <0.01
Sepsis-2 organ dysfunction, n (%)
No organ dysfunction 5 (2) 281 (98) <0.01 0 (0) 212 (47) <0.01
Neurologic 30 (13) 7 (2) <0.01 52 (27) 91 (20) 0.05
Cardiovascular 174 (91) - - 126 (66) 130 (29) <0.01
Respiratory 63 (27) - - 112 (59) 83 (18) <0.01
Renal 28 (12) - - 50 (26) 33 (7) <0.01
Haematological 25 (11) - - 19 (10) 26 (6) 0.05
Hepatic 9 (4) - - 7 (4) 6 (1) 0.06
Intensive Care, n (%) 14 (6) - - 18 (10) 30 (7) 0.25
Three-days mortality, n (%) 3 (1) - - 7 (4) 18 (4) 0.86
3.1.2. Performances of the Risk Stratification Scores for the Composite Outcome and Mortality
NEWS2 had a significantly higher AUC, 0.80 (95% CI 0.75–0.83), than qSOFA, 0.71 (95%
CI 0.66–0.75), p < 0.01. The suggested cut-off of ≥2 qSOFA was specific, 97% (95% CI 0.95–0.99),
but yielded low sensitivity, 17% (95% CI 0.12–0.22). Cross tabulations, sensitivity, specificity, AUC and
Odds Ratio (OR) for qSOFA and NEWS2 can be found in Table 3.
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Table 3. Accuracy of risk stratification scores.
qSOFA NEWS2
≥2 <2 ≥ 5 <5
Cohort A (n = 526)
Composite outcome + 40 198 155 83
Composite outcome – 8 280 57 231
Sensitivity 0.17 (0.12–0.22) 0.65 (0.59–0.71)
Specificity 0.97 (0.95–0.99) 0.80 (0.75–0.85)
AUC 0.71 (0.66–0.75) 0.80 (0.75–0.83)
p compared to qSOFA reference <0.01
30-days mortality + 6 7 9 4
30-days mortality – 42 471 203 310
AUC 30-days
mortality 0.72 (0.54–0.90) 0.75 (0.60–0.90)
Cohort B (n = 645)
Composite outcome + 67 124 160 31
Composite outcome – 75 379 287 167
Sensitivity 0.35 (0.28–0.42) 0.84 (0.78–0.89)
Specificity 0.83 (0.80–0.87) 0.37 (0.32–0.41)
AUC 0.62 (0.57–0.67) 0.70 (0.65–0.74)
p compared to qSOFA reference 0.02
30-days mortality + 18 32 45 5
30-days mortality – 79 338 289 128
AUC 30-days
mortality 0.62 (0.53–0.70) 0.70 (0.63–0.70)
95% CI within brackets. AUC (area under receiver operating characteristic curve). qSOFA (Quick Sequential Organ
Failure Assessment). NEWS2 (National Early Warning Score 2).
3.1.3. The Effect of Adding Biomarkers to qSOFA and NEWS2
The effect of adding lactate or HBP to qSOFA and NEWS2, respectively, was analysed in the
485 patients with biomarkers available. In these analyses organ dysfunction due to hyperlactaemia was
excluded from the outcome. There was no significant improvement of adding lactate to qSOFA. With
the addition of one point for lactate > 2.0 mmol/L to qSOFA, the AUC was increased from 0.70 (95%
CI 0.66–0.75) to 0.73 (95% CI 0.68–0.77), p = 0.37.
The addition of one point for HBP > 30 ng/mL increased the AUC for qSOFA from 0.70
(95% CI 0.66–0.75) to 0.78 (95% CI 0.74–0.82), p = 0.01 (Table 4).
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Table 4. Accuracy of risk stratification scores with biomarkers. 95% CI within brackets. Organ dysfunction (OD).
qSOFA qSOFA Incl Lactate qSOFA Incl HBP NEWS2 NEWS2 Incl Lactate NEWS2 Incl HBP
Cohort A, n = 485
Composite outcome excl lactate and CNS OD
AUC 0.70 (0.66–0.75) 0.73 (0.68–0.77) 0.78 (0.74–0.82) 0.79 (0.75–0.83) 0.80 (0.76–0.84) 0.81 (0.78–0.85)
p compared to qSOFA reference 0.37 0.01 <0.01 <0.01 <0.01
p compared to NEWS2 <0.01 0.06 0.74 reference 0.73 0.73
Composite outcome incl lactate excl CNS OD
AUC 0.71 (0.66–0.75) 0.74 (0.70–0.78) 0.78 (0.74–0.82) 0.79 (0.75–0.83) 0.80 (0.76–0.84) 0.82 (0.78–0.85)
p compared to qSOFA reference 0.47 0.03 0.01 <0.01 <0.01
p compared to NEWS2 0.01 0.11 0.73 reference 0.73 0.30
Composite outcome incl lactate and CNS OD
AUC 0.72 (0.68–0.77) 0.76 (0.71–0.80) 0.80 (0.76–0.84) 0.81 (0.77–0.85) 0.82 (0.78–0.86) 0.83 (0.80–0.87)
p compared to qSOFA reference 0.21 0.01 <0.01 <0.01 <0.01
p compared to NEWS2 <0.01 0.09 0.73 reference 0.72 0.47
Cohort B, n = 358
Composite outcome excl lactate and CNS OD
AUC 0.62 (0.55–0.68) 0.64 (0.58–0.70) 0.66 (0.60–0.73) 0.67 (0.61–0.73) 0.68 (0.62–0.73) 0.69 (0.63–0.75)
p compared to qSOFA reference 0.66 0.37 0.26 0.18 0.11
p compared to NEWS2 0.26 0.50 0.82 reference 0.82 0.65
Composite outcome incl lactate excl CNS OD
AUC 0.62 (0.55–0.68) 0.64 (0.58–0.70) 0.66 (0.60–0.73) 0.67 (0.61–0.73) 0.68 (0.62–0.73) 0.69 (0.63–0.75)
p compared to qSOFA reference 0.66 0.37 0.26 0.18 0.11
p compared to NEWS2 0.26 0.50 0.82 reference 0.82 0.65
Composite outcome incl lactate and CNS OD
AUC 0.62 (0.56–0.68) 0.64 (57–0.70) 0.67 (0.61–0.73) 0.68 (0.62–0.74) 0.68 (0.62–0.74) 0.69 (0.63–0.75)
p compared to qSOFA reference 0.66 0.26 0.18 0.18 0.11
p compared to NEWS2 0.18 0.36 0.82 reference 1 0.82
95% CI within brackets. qSOFA (quick Sequential Organ Failure Assessment). NEWS2 (National Early Warning Score 2). OD (organ dysfunction). CNS (central nervous system). HBP
(heparin binding protein).
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3.1.4. Sensitivity Analyses—Outcome
The evaluations of the risk stratification scores were repeated with acute neurological dysfunction
as organ dysfunction defining severe sepsis. This did not significantly change the results. The same
was true when adding hyperlactaemia as organ dysfunction to the analyses with lactate and HBP
(Table 4).
3.1.5. Sensitivity Analyses—Missing Data
The analyses for the diagnostic accuracy for qSOFA and NEWS2 with and without lactate or
HBP were repeated after multiple imputation of missing data. This was performed for the 29 patients
excluded for missing data and for 41 patients included in the primary analysis but with missing
biomarkers. For missing data, see Table S4. Data were assumed to be missing at random. Distribution
of variables were similar for patients with missing values and patients with complete data. Variables
imputed were systolic blood pressure, heart frequency, respiratory frequency, temperature, mental
status, SaO2, oxygen treatment, lactate and HBP. Other parameters in the imputation although not
imputed were comorbidities and outcome. The models were validated by plots of imputations
and iterations.
The performances of the risk stratification scores were analysed in imputed data sets, (Table S5).
The analyses using multiple imputation yielded similar estimates as the analyses of the original data.
3.2. Cohort B—Patients, with and without Infection
3.2.1. Patient Demographics
Seventy-three patients were excluded from the study due to missing data. Of the 645 patients
included in the primary analyses, 269 (42%) had a diagnosed infection. The composite outcome of
sepsis with organ dysfunction was experienced in 191 (30%), i.e., admission to intensive care due to
an infection or infection-related mortality within 72 h from enrolment (Figure 1). Data on patient
characteristics are presented in Table 2.
Patients with a probable or proven infection had a 30-day mortality rate of 12%. Patients without
an infection had a 30-day mortality rate of 9%.
Of the patients included in the study, 287 with missing lactate or HBP-analysis were excluded
when the effect of adding lactate or HBP to qSOFA and NEWS2 were studied. The large number
of missing analyses was because all blood samples with signs of haemolysis were discarded in the
original study.
3.2.2. Performance of the Risk Stratification Scores for the Composite Outcome and Mortality
Cross tabulations, sensitivity, specificity, AUC and OR for qSOFA and NEWS2 are presented in
Table 3. NEWS2 had significantly higher AUC, 0.70 (95% CI 0.65–0.74), than qSOFA, AUC 0.62 (95%
CI 0.57–0.67), p = 0.02.
3.2.3. The Effect of Adding Biomarkers to qSOFA and NEWS2
The effect of adding lactate or HBP to qSOFA and NEWS2, respectively, was analysed in the
358 patients with biomarkers available. In these analyses organ dysfunction due to hyperlactaemia was
excluded. There was no effect of adding lactate to qSOFA. Without and with the addition of one point for
lactate > 2.0 mmol/L the AUC increased slightly from 0.62 (95% CI 0.55–0.68) to 0.64 (95% CI 0.58–0.70)
although not significantly (p = 0.66). Neither did the addition of one point for HBP > 30 ng/mL
improve qSOFA significantly, although the AUC increased from 0.62 (95% CI 0.55–0.68) to 0.66 (95%
CI 0.60–0.73), p = 0.37 (Table 4).
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3.2.4. Sensitivity Analyses—Outcome
As in Cohort A, the evaluations of the risk stratification scores were repeated with acute neurological
dysfunction as an organ dysfunction, without significant effect on the results. Hyperlactaemia excluded
as an organ dysfunction resulted in no significant alterations of the results (Table 4).
3.2.5. Sensitivity Analyses—Missing Data
The analyses for the primary outcome were repeated after multiple imputation of missing data for
62 patients were excluded for missing data, and 287 patients with missing biomarkers. For missing data,
see Table S4. Data were assumed to be missing at random. Distribution of variables were similar for
patients with missing values and patients with complete data. Variables imputed were systolic blood
pressure, heart frequency, respiratory frequency, temperature, mental status, SaO2, oxygen treatment,
lactate and HBP. Other parameters in the imputation although not imputed were comorbidities and
outcome. The models were validated by plots of imputations and iterations.
The performances of scores were analysed in imputed data sets, see Table S5, the analyses using
multiple imputation yielded similar estimates as the analyses of the original data.
3.2.6. Sensitivity Analyses—Inclusion Bias
To assess the possible inclusion bias due to convenience inclusion in Cohort A and at one site in
Cohort B, a sub analysis was performed. The subgroup of Cohort A that fulfilled the inclusion criteria
for Cohort B and the subgroup of Cohort B that were included consecutively and fulfilled the inclusion
criteria for Cohort A was compared for performances of the risk stratification scores.
The subgroup of Cohort A consisted of 190 patients of whom 129 had the composite outcome.
AUC for NEWS2 was 0.79 (95% CI 0.72–0.85) and for qSOFA 0.67 (95% CI 0.59–0.75).
The subgroup of Cohort B consisted of 171 patients, 118 with the composite outcome. The AUC
for NEWS2 was 0.77 (95% CI 0.70–0.84) and for qSOFA was 0.69 (95% CI 0.61–0.78).
To further assess if any inclusion bias in Cohort A could have skewed the results a sensitivity
analysis was made addressing the proportion of patients with organ dysfunction in the cohort. In Cohort
A the proportion of patients developing any organ dysfunction (excluding neurological dysfunction)
was 46%. Patients were divided in two groups as to the presence or absence of organ dysfunction
and new samples were drawn from respective groups until a new cohort of 1000 patients was created.
The sampling was adjusted so that the proportion of patients with organ dysfunction varied from
1%–99% in steps of 1%. For each cohort, the AUC for the composite outcome was calculated (Figure S1).
Across all proportions of patients with organ dysfunction, the AUCs for NEWS2 were superior to the
AUCs for qSOFA. This generalizability of the results suggests that even if there might have been an
inclusion bias possibly leading to an overrepresentation of patients with organ dysfunction the result,
that NEWS2 is superior to qSOFA, would still be valid.
4. Discussion
In this evaluation of risk stratification scores for sepsis in the ED, NEWS2 was superior to qSOFA
in screening for the composite outcome; sepsis with organ dysfunction, infection-related mortality
or intensive care due to an infection. The superiority of NEWS2 compared to qSOFA was true both
among infected patients (Cohort A) as well as undifferentiated patients (Cohort B).
In agreement with the finding by Seymour et al. accuracy did not improve through addition
of lactate to qSOFA [4]. HBP has previously been shown to be superior to lactate in predicting
sepsis [19,25] and thus the addition of HBP to qSOFA was tested. HBP improved the performance
of qSOFA significantly in infected patients (Cohort A) but NEWS2 still performed better. NEWS has
previously been shown to be superior to qSOFA for detection of sepsis at ED [26]. NEWS2 differs
from NEWS in including different SaO2-scales and the addition of altered mentation, which is why the
higher AUC for NEWS2 than qSOFA in this study was not surprising [7].
J. Clin. Med. 2019, 8, 1128 10 of 13
The higher AUCs in Cohort A for both scores, which were due to higher specificities yet
lower sensitivities, is likely multifactorial. Of particular importance was that Cohort A was more
homogeneous, consisting only of infected patients and also due to the differences in inclusion criteria.
Whether a study determines a risk stratification score to be of value is highly dependent upon
the chosen outcome. Many prior studies regarding qSOFA have used mortality as the primary
outcome [27,28]. However, focusing only on mortality implies that worsening in physiologic outcomes
are not clinically important. As long-term effects of sepsis have become more apparent, the development
of sepsis itself is an important outcome [29–31].
Compared to studies with mortality as the primary outcome, the AUC and sensitivity of qSOFA
was somewhat lower in our study, however this agreed with previous studies using sepsis as the
primary outcome [10,12,32,33]. Evaluating in reference to the most severely ill patients might lead
to overestimation of sensitivity and negative predictive value. A recent study by Usman et al. used
severe sepsis as outcome but with higher AUC for qSOFA than in the present study. The inclusion
of central nervous dysfunction in the outcome as well as the shorter period evaluated for sepsis
probably contributed to the higher AUC; for several patients in our study sepsis was detected after
eight hours [21,26]. Although we found very high specificity, the poor sensitivity of two qSOFA points
diminishes its usefulness in an ED setting when screening for a condition like sepsis, which aims to catch
all potential patients for rapid treatment [3]. We included 30-day mortality as a secondary outcome.
The mortality in both cohorts was low, generating wide confidence intervals for 30-day mortality.
Strengths of the study included an independent physician review of whether infection and
organ dysfunction were present, use of a composite outcome i.e., sepsis with organ dysfunction,
infection-related mortality or intensive care due to an infection provides a “real world utility”.
This composite score provides a more global view of patient outcome than the in-hospital
mortality [4,32,34,35]. The weakness of the composite score was that several parameters in the risk
stratification scores also define organ dysfunction and thus sepsis. Hence, risk stratification scores
with these sepsis-defining parameters can be misleading when evaluated against sepsis. Unlike other
studies, we tried to minimize this bias by excluding organ dysfunction of the central nervous system
from the outcome. Furthermore, when evaluating the effect of adding lactate to the risk stratification
scores, hyperlactaemia was excluded from the sepsis definition [11,26,33]. To further elaborate on this,
we repeated the analyses with acute neurological dysfunction as well as hyperlactaemia included as
organ dysfunctions with no significant alterations in results. These findings illustrated the robustness
of our analysis.
One might fear that also other parameters such as vital signs which were present in the scores as
well in the definition of sepsis might skew the results. However, this bias was inevitable since there is
no gold standard diagnostic test for sepsis against which different scores can be compared. One method
to probe this bias would be to instead address the predictive validity, which evaluates the relative
performance of the score by their ability to identify those patients at increased risk for downstream
events associated with the condition of interest. In the context of this, attributable mortality (adjusted
for known risk factors) could have been performed. However, we felt this approach did not significantly
reduce the bias.
A weakness of the study was the inclusion criteria in Cohort B. Some of the lower limits for
inclusion criteria are in fact above those needed for points to accrue in the scoring systems, which may
have affected the results. For example, in Cohort B, patients with a respiratory rate below 25 might
have been excluded. This group may contain patients with all kinds of classifications according to
the scores and outcome and we could not properly foresee how it affected the performances of the
scores. Furthermore, these criteria for inclusion were also likely to favour inclusion of more severely ill
patients than the inclusion of all ED patients thus giving a higher mortality in Cohort B compared
to other ED cohorts where all patients with ED encounters were included. However, the threshold
for seeking the ED varies depending on the location and whether a referral or not is mandatory or
if the ED is the primary site where people seek medical advice for illnesses and hence we felt it was
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necessary to establish predefined inclusion criteria. Many other studies have instead only included
patients admitted to the hospital but since admittance criteria differ between hospitals and countries
we preferred to use predefined inclusion criteria based on vital parameters.
Another weakness was the potential selection bias caused by convenience inclusion of patients in
Cohort A and at one site in Cohort B. There may have been a risk that patients with sepsis were more
often included than patients without sepsis and that one scoring system might have been favoured in
front of the other. To address this a sensitivity analyses compared the sub cohort of patients that were
consecutively included with convenience-included patients from the Cohort A. The sensitivity analysis
rendered similar performances of the risk stratification scores. This suggests that inclusion bias was
unlikely. However, this analysis did not completely exclude a selection bias of patients in Cohort A
not fulfilling the inclusion criteria of Cohort B. To address this possibility another sensitivity analysis
was made. Statistically simulated cohorts were created where the proportion of patients with organ
dysfunction varied between 1% and 99% and across the range of frequencies NEWS2 had a higher
AUC than qSOFA. This sensitivity analysis demonstrated a robustness in the results and indicated that
even if there might have been an inclusion bias possibly leading to overrepresentation of patients with
organ dysfunction, the superiority of NEWS2 versus qSOFA would still be valid in cohorts with lower
frequencies of patients with organ dysfunctions.
qSOFA was proposed to identify those who are more likely to have a poor outcome among
patients with a suspected infection [4]. It was also suggested that patient with ≥2 qSOFA should
prompt consideration of infection [13]. Furthermore, the rationale for suspecting infection is highly
variable. For example, in Cohort B, 33% of those seeking with infection had no infection, while 34%
of those found later to have an infection, had a chief complaint unrelated to infection. This lack of
initial diagnostic precision is why we wanted to evaluate the qSOFA, NEWS2 and biomarkers in both a
cohort of only infected patients as well as in a cohort of undifferentiated patients.
5. Conclusions
To the best of our knowledge, NEWS2 has not been evaluated for its ability to predict sepsis in
patients presenting to the ED, nor has it been compared with qSOFA for this purpose. In this study we
compared the ability of NEWS2 and qSOFA to predict sepsis both among infected patients and among
undifferentiated patients in the ED. We found that NEWS2 was superior to qSOFA for detecting sepsis
with organ dysfunction, admission to intensive care due to an infection and infection-related mortality.
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